|
RAD21 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.19959999606212E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.04519999947151E-07 |
| Normal-vs-Stage2 |
2.02949999994484E-06 |
| Normal-vs-Stage3 |
1.09410003279464E-09 |
| Normal-vs-Stage4 |
1.32790000106908E-08 |
| Stage1-vs-Stage2 |
3.287200E-01 |
| Stage1-vs-Stage3 |
3.296300E-03 |
| Stage1-vs-Stage4 |
5.907800E-02 |
| Stage2-vs-Stage3 |
2.896200E-01 |
| Stage2-vs-Stage4 |
4.998600E-01 |
| Stage3-vs-Stage4 |
7.068600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.04189999855708E-08 |
| Normal-vs-AfricanAmerican |
1.758540E-03 |
| Normal-vs-Asian |
1.94060000002771E-06 |
| Caucasian-vs-AfricanAmerican |
4.028800E-01 |
| Caucasian-vs-Asian |
8.487400E-01 |
| AfricanAmerican-vs-Asian |
5.543800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.25469999945338E-07 |
| Normal-vs-Female |
3.55620000114243E-08 |
| Male-vs-Female |
9.015400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.30449999480709E-08 |
| Normal-vs-Age(41-60Yrs) |
2.27999999991013E-08 |
| Normal-vs-Age(61-80Yrs) |
2.30679997326177E-09 |
| Normal-vs-Age(81-100Yrs) |
6.259800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.766400E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.087640E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.333000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.983000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.948800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.197400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.076100E-02 |
| Classical-VS-Follicular |
3.210000E-01 |
| Classical-VS-Other |
6.334800E-01 |
| Classical-VS-Normal |
6.82499999959951E-07 |
| Tall-VS-Follicular |
3.670400E-01 |
| Tall-VS-Other |
6.907200E-01 |
| Tall-VS-Normal |
8.22650000342762E-08 |
| Follicular-VS-Other |
9.355800E-01 |
| Follicular-VS-Normal |
1.11420000004081E-07 |
| Other-VS-Normal |
1.933650E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.59340326991264E-11 |
| Normal-vs-N1 |
8.40130000012707E-08 |
| N0-vs-N1 |
4.763600E-01 |
|
|
